• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Mumbai, Aug. 28

Ipca Laboratories Ltd has entered into a collaborative-cum-licence agreement with Central Drug Research Institute (CDRI) for the further development of its compound 99/411, a promising synthetic substitute for malarial drugs based on Artemisinin. Artemisinin based combination therapy has been recommended by the World Health Organisation for the treatment of P. falciparum malaria. A synthetic substitute of artemisinin will be a breakthrough in cost effective management of f alciparum malaria and multi-drug resistant falciparum malaria in clinical practice, a note from the company said. CDRI-Lucknow is under the Council of Scientific and Industrial Research and is engaged in areas like anti-malarial, tuberculosis and reproductive health along with lifestyle and age related disorders. The compound under licensing is being developed in an oral form to meet new global challenges of the malaria incidence covering 300-400 million patients every year including the Indian population of around 3 million, the company said. The company spends four per cent of its turnover on research.

– Our Bureau

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
IOC pilot project to deliver LNG at doorstep

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line